Literature DB >> 8409436

Protective immunity in baboons vaccinated with a recombinant antigen or radiation-attenuated cercariae of Schistosoma mansoni is antibody-dependent.

L A Soisson1, G D Reid, I O Farah, M Nyindo, M Strand.   

Abstract

Mice vaccinated with radiation-attenuated cercariae of Schistosoma mansoni exhibit high levels of resistance to challenge infection. We have previously shown that sera from these mice recognize polypeptides that are expressed on the surface of newly transformed schistosomula. We have cloned and sequenced a cDNA that encodes a 62-kDa portion of one of these polypeptides. Vaccination of mice with this 62-kDa polypeptide (designated rlrV-5) elicits high antibody titers and significant resistance to challenge infection. We report here the results of a vaccination trial in baboons with the rlrV-5 or radiation-attenuated cercariae. rlrV-5 was presented either in the form of protein micelles or complexed with the outer membrane protein of meningococcus to form proteosomes. The level of protection achieved in these groups ranged from 0 to 54%, with a mean of 27.7%. In baboons exposed to radiation-attenuated cercariae the level of protection was very high, with a mean of 84%. The resistance observed after vaccination with rlrV-5 or radiation-attenuated cercariae was reflected in the overall histopathology. Vaccination of baboons with rlrV-5 or radiation-attenuated cercariae elicited an antibody response against epitopes exposed on the surface of newly transformed schistosomula. In the case of baboons vaccinated with radiation-attenuated cercariae, this response was not limited to epitopes encompassed by rlrV-5. Analysis of individual baboon sera by ELISA demonstrated that there was a direct correlation between the anti-rlrV-5 titer and resistance to challenge worm burden, suggesting that the immunoprotective mechanism is antibody-dependent.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8409436

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni.

Authors:  T Ben-Yedidia; R Tarrab-Hazdai; D Schechtman; R Arnon
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Human immune responses to Schistosoma mansoni vaccine candidate antigens.

Authors:  A Ribeiro de Jesus; I Araújo; O Bacellar; A Magalhães; E Pearce; D Harn; M Strand; E M Carvalho
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

3.  Morbidity and immune response to natural schistosomiasis in baboons ( Papio anubis).

Authors:  Idle Farah; Andreas Börjesson; Thomas Kariuki; Dorcas Yole; Mbaruk Suleman; Jann Hau; Hans-Erik Carlsson
Journal:  Parasitol Res       Date:  2003-09-18       Impact factor: 2.289

4.  Parameters of the attenuated schistosome vaccine evaluated in the olive baboon.

Authors:  Thomas M Kariuki; Idle O Farah; Dorcas S Yole; Jason M Mwenda; Govert J Van Dam; André M Deelder; R Alan Wilson; Patricia S Coulson
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

5.  Previous or ongoing schistosome infections do not compromise the efficacy of the attenuated cercaria vaccine.

Authors:  Thomas M Kariuki; Govert J Van Dam; André M Deelder; Idle O Farah; Dorcas S Yole; R Alan Wilson; Patricia S Coulson
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

6.  Transmission electron microscopic observations on ultrastructural alterations in Schistosoma mansoni adult worms recovered from C57BL/6 mice treated with radiation-attenuated vaccine and/or praziquantel in addition to passive immunization with normal and vaccinated rabbit sera against infection.

Authors:  Eman A El-Shabasy; Enayat S Reda; Sherif H Abdeen; Ashraf E Said; Allal Ouhtit
Journal:  Parasitol Res       Date:  2015-02-18       Impact factor: 2.289

7.  Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine.

Authors:  Weidong Zhang; Gul Ahmad; Workineh Torben; Zahid Noor; Loc Le; Raymond T Damian; Roman F Wolf; Gary L White; Maria Chavez-Suarez; Ronald B Podesta; Ronald C Kennedy; Afzal A Siddiqui
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

8.  Structural changes of Schistosoma mansoni adult worms recovered from C57BL/6 mice treated with radiation-attenuated vaccine and/or praziquantel against infection.

Authors:  Enayat S Reda; Allal Ouhtit; Sherif H Abdeen; Eman A El-Shabasy
Journal:  Parasitol Res       Date:  2011-08-09       Impact factor: 2.289

Review 9.  Vaccines to combat the neglected tropical diseases.

Authors:  Jeffrey M Bethony; Rhea N Cole; Xiaoti Guo; Shaden Kamhawi; Marshall W Lightowlers; Alex Loukas; William Petri; Steven Reed; Jesus G Valenzuela; Peter J Hotez
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

10.  Molecular cloning, purification and characterisation of myosin of human lymphatic filarial parasite Brugia malayi.

Authors:  S K Verma; I Bansal; S Vedi; J K Saxena; V M Katoch; S M Bhattacharya
Journal:  Parasitol Res       Date:  2007-12-07       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.